Business
LMF Acquisition Opportunities, Inc. Stockholders Approve Previously Announced Business Combination with SeaStar Medical, Inc.
Transaction anticipated to close upon satisfaction of all closing conditions DENVER and TAMPA, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- LMF Acquisition
About this update from Seastar Medical Holding Corporation
[{"type":"text","content":"Transaction anticipated to close upon satisfaction of all closing conditions\nDENVER and TAMPA, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ: LMFA), and SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that LMAO stockholders voted to approve the previously proposed business combination with SeaStar Medical at LMAO’s special meeting of LMAO stockholders (the “Special Meeting”) held earlier today, October 18, 2022. More than 96% of the votes cast at the meeting voted to approve the business combination with SeaStar Medical. Holders of approximately 79% of LMAO’s issued and outstanding shares cast votes at the Special Meeting. The business combination is expected to close upon satisfaction of all closing conditions, at which time LMAO will be renamed “SeaStar Medical Holding Corporation” and the company’s common stock and warrants are expected to begin trading on Nasdaq under the new ticker symbols \"ICU\" and “ICUCW,” respectively. The formal results of the vote will be included in a Current Report on Form 8-K to be filed by LMAO with the U.S. Securities and Exchange Commission, which will be available at www.sec.gov. About SeaStar Medical, Inc. Denver-based SeaStar Medical, Inc. is a medical technology company that is focusing on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit http://www.seastarmedical.com/ or visit us on LinkedIn or Twitter. About LMF Acquisition Opportunities, Inc. LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar b...